Brian Klein

Brian Klein is an Analyst at Kingdon Capital Management in New York, NY, where he is responsible for conducting research and investment analysis, with a particular focus on the biotechnology and healthcare sectors. At Kingdon Capital, Klein leverages his deep expertise to identify promising biotech investment opportunities and provide informed recommendations in support of the firm’s long/short equity strategies.

Prior to joining Kingdon Capital Management in 2015, Klein held senior roles in healthcare equity research, including serving as Senior Biotechnology Analyst and Vice President at Stifel Nicolaus, as well as Biotechnology Analyst, Vice President at Lazard Capital Markets. His extensive experience in the life sciences sector encompasses coverage of public and private biotech companies, industry trends, and drug development pipelines.

Klein holds a Doctor of Medicine degree from New York Medical College, a Master of Science in Biophysics and Physiology from Georgetown University, and a Bachelor of Arts in Economics from Yale University. This unique blend of medical, scientific, and financial training has enabled him to make significant contributions to biotech investing, applying clinical insights to fundamental investment analysis and portfolio management.